NCT06530251 - A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter

Enrollment

280

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2028

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

AK112

Following a predefined dose and date.

DRUG

Cadonilimab

Following a predefined dose and date.

DRUG

AK127

Following a predefined dose and date.

DRUG

AK130

Following a predefined dose and date.

DRUG

Sintilimab Injection

Following the local label direction.

DRUG

Bevacizumab biosimilar

Following the local label direction.

Trial Locations (2)

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital), Jinan